Drotrecogin alfa (Activated) in severe sepsis: a systematic review of observational studies (Update of Report 29)
Nicolau I, Pan I, Xie X, McGregor M, Dendukuri N
Record ID 32012000901
English
Authors' recommendations:
• The mortality rates reported in the observational studies we reviewed, were higher than the rates previously reported
in RCTs (PROGRESS and ADDRESS).
• Studies that included a comparison group of patients not treated with DrotAA, generally concluded that there was a
beneficial effect of DrotAA treatment.
• The majority of studies reported being supported by the manufacturer.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.mcgill.ca/tau/files/tau/muhc_tau_2012_58_sepsis_a.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Sepsis
- Anti-Infective Agents
- Recombinant Proteins
- Protein C
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, 536-5100 Boul. Maisonneuve O, Montreal, H4A 3T2
Contact Name:
eva.suarthana@mcgill.ca
Contact Email:
nisha.almeida@muhc.mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.